In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE Healthcare aims to end unpredictability in early drug research

This article was originally published in Scrip

Executive Summary

Better consistency of the cells used in early-stage drug research could save R&D departments millions of dollars and a lot of wasted time and effort. At GE Healthcare, the commercialisation of reliable stem cell lines is just around the corner, head of cell technologies R&D Dr Stephen Minger tells Ashley Yeo.

You may also be interested in...

Device Week, 3 July 2020 – Asia Regulatory Update & International Medical Device School

This week's Device Week podcast covers recent regulatory developments in Asia in the wake of COVID-19, and how regulators are adjusting to working under the pandemic. Having published two updates from our regular Asian Medtech Associations Reg Networking discussions this week, Medtech Insight speaks to Asia Regulatory Professional Association founder Jack Wong on Asian regulatory themes and South Korea's hosting of the next International Medical Device School.

Asian Medtech Associations Reg Networking: ASEANMed Drives Medtech Agenda Forward Despite COVID-19 – Part Two

The Asian Medtech Associations Regulatory Networking discussions this month centered on strategies to control COVID-19 locally and the activities of the ASEANMed industry association. This editorial feature is hosted by Medtech Insight, along with the ARQon Asia Regulatory and Quality Consultancy and the Asia Regulatory Professional Association. This is the second of two articles on the discussions.

ResMed Ready To Supply Digital Answers To Health Care’s Demand Challenges

ResMed’s respiratory device portfolio has put it front and center of the global medtech industry’s efforts to bring COVID-19 under control. UK and Ireland country manager Antoine Valterio tells In Vivo how the company rose to the challenge, and how providers are now seeing digital technologies in a new light.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts